Irritable Bowel Clinical Trial
Official title:
Effect of 6 Weeks Daily Consumption of a Cereal-based Juice Beverage on Gastrointestinal Health
The project is a randomized, 2-way, blinded parallel trial in which 56 healthy adults of both
genders with frequent occurrence of stomach trouble.This intervention trial with 6 weeks of
daily intake β-glucans will be carried out with a beverage containing β-glucans and a control
beverage without β-glucans. The primary aim is to investigate whether β-glucans from barley
has an effect on stomach and intestinal health, including stool volume and frequency.
Microbiota, concentrations of short chain fatty acids (butyrate, propionate, acetate),
calprotectin, and energy and fat content in feces. Furthermore, blood pressure and exhaled
hydrogen and methane, before and after the intervention, subjective perception of
gastrointestinal problems and digestion as well as the participants' attitudes towards
functional foods are measured using Visual Analog Scale (VAS).
Further, specific metabolites of β-glucans in urine (exploratory endpoint) and certain toxic
metabolites from the microbiota using metabolite profiling (metabolomics) are also analyzed
β-glucans from barley slows gastric emptying rate and prolongs the transit time of food in the small intestine." The relatively undigested β-glucans have the ability to increase satiety and stimulate digestion, ensuring regular bowel movements and relieve sluggish bowel movements, including constipation and constipation. β-glucans are fermented down in the large intestine, resulting in production of short-chain fatty acids which inhibit the biosynthesis of cholesterol, hence blood cholesterol levels are lowered (not the goal here). Subsequently, β-glucans may also affect blood pressure. As a direct result of the effects in the intestine, there will be an improvement in the quality of life for people with stomach upsets and maybe a reduction in the risk of cardiovascular disease. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05619341 -
Effect of Rate Of Delivery on Colonic Fermentation of inuliN (EON)
|
N/A | |
Completed |
NCT05811663 -
Health Care Use and Costs of Functional Somatic Disorders
|
||
Completed |
NCT06006715 -
Psychiatric Disorders and Functional Somatic Disorders
|
||
Enrolling by invitation |
NCT04011943 -
Fecal Microbiota Transplantation for Health Improvement (TFM3)
|
N/A | |
Completed |
NCT04245254 -
GutMe!: IBS and Collagen Protein Powder an Interventional Study
|
N/A | |
Recruiting |
NCT04214470 -
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in IBS
|
||
Completed |
NCT02742597 -
Patient-Centred Innovations for Persons With Multimorbidity - Ontario
|
N/A | |
Active, not recruiting |
NCT05463900 -
Microbial and Human Determinants of the Onset of IBD Flares
|
||
Completed |
NCT02789800 -
Patient-Centred Innovations for Persons With Multimorbidity - Quebec
|
N/A |